Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pharma-Bio Serv (PBSV) Net Margin (2016 - 2026)

Pharma-Bio Serv's Net Margin history spans 16 years, with the latest figure at 1.43% for Q1 2026.

  • For Q1 2026, Net Margin rose 109.0% year-over-year to 1.43%; the TTM value through Jan 2026 reached 0.97%, up 422.0%, while the annual FY2025 figure was 1.12%, 706.0% up from the prior year.
  • Net Margin reached 1.43% in Q1 2026 per PBSV's latest filing, up from 0.0% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 11.5% in Q3 2023 to a low of 12.79% in Q3 2024.
  • Average Net Margin over 5 years is 0.72%, with a median of 1.43% recorded in 2026.
  • The largest YoY upside for Net Margin was 9079bps in 2022 against a maximum downside of -3958bps in 2022.
  • A 5-year view of Net Margin shows it stood at 3.74% in 2022, then plummeted by -135bps to 1.31% in 2023, then soared by 153bps to 0.69% in 2024, then plummeted by -101bps to 0.0% in 2025, then surged by 30276bps to 1.43% in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Net Margin are 1.43% (Q1 2026), 0.0% (Q4 2025), and 10.89% (Q3 2025).